Inactivated sars-cov-2 virus vaccine
AssigneeValneva Austria GmbH
InventorsAndreas Meinke, Michael Möhlen, Robert Schlegl, Jürgen Heindl-Wruss
Life of this patent
Estimating the term…
Abstract
Described herein are SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
Claims21
-64. (canceled)
A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine comprising a beta-propiolactone-inactivated SARS-CoV-2 particle, wherein the vaccine is capable of generating neutralizing antibodies against native SARS-CoV-2 particles in a human subject, and wherein the SARS-CoV-2 particle is inactivated at a beta-propiolactone (BPL) concentration of 0.01 to 0.1% by weight.
A method of producing a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, comprising:
- (a) producing native SARS-CoV-2 particles;
- (b) inactivating the native SARS-CoV-2 particles with beta-propiolactone (BPL) to obtain inactivated SARS-CoV-2 particles;
- (c) incorporating the inactivated SARS-CoV-2 particles into a vaccine composition;
- wherein a native surface conformation of the SARS-CoV-2 particle is preserved in the inactivation step, such that the vaccine is capable of generating neutralizing antibodies against native SARS-CoV-2 particles in a human subject, and wherein the concentration of BPL in the inactivation step is 0.01 to 0.1% by weight.
Dependencies are inferred from the claim text.